Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dato-DXd (Yale Univ.)
- Development stage
- Preclinical
- Lead developer
- Yale University
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Dato-DXd (Yale Univ.): sourced facts only. name: "Datopotamab deruxtecan (Dato-DXd) is a novel ADC composed of the humanized anti-TROP2 IgG1 monoclonal antibody, a cleavable tetrapeptide linker, and a topoisomerase I inhibitor payload." [DOI:10.1158/1538-7445.am2025-5642]; target: "Datopotamab deruxtecan (Dato-DXd) is a novel ADC composed of the humanized anti-TROP2 IgG1 monoclonal antibody, a cleavable tetrapeptide linker, and a topoisomerase I inhibitor payload." [DOI:10.1158/1538-7445.am2025-5642]; developer: "Yale University, New Haven, CT." [DOI:10.1158/1538-7445.am2025-5642]; modality: "Datopotamab deruxtecan (Dato-DXd) is a novel ADC composed of the humanized anti-TROP2 IgG1 monoclonal antibody, a cleavable tetrapeptide linker, and a topoisomerase I inhibitor payload." [DOI:10.1158/1538-7445.am2025-5642]; stage: "In vivo, Dato-DXd demonstrated a significant survival advantage in mice xenografted with ARK2 compared to the other treatment groups (p<0.0001)." [DOI:10.1158/1538-7445.am2025-5642]
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on Dato-DXd (Yale Univ.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dato-DXd (Yale Univ.).